Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case

Thomas Powles, MBBS, MRCP, MD, discusses how upon examining an elderly patient experiencing hematuria, they were found to have had a transurethral resection of a bladder tumor, which revealed the presence of muscle-invasive bladder cancer. The patient is determined to have metastatic disease and is ineligible for cisplatin chemotherapy in the first line.